menotropins and Breast-Neoplasms

Topics: Age Factors; Arteriosclerosis; Arthritis; Breast Neoplasms; Contraception; Cross-Cultural Comparison; Estrogens; Family Planning Services; Female; Humans; Menopause; Menopause, Premature; Menotropins; Middle Aged; Osteoporosis; Racial Groups; Research; Uterine Neoplasms

To present a case of twin pregnancy obtained by in vitro fertilization and embryo transfer (IVF-ET) with variable dose letrozole-FSH protocol of lower peak estradiol level, after treatment of carcinoma of the breast.. A 34-year-old patient diagnosed with mucinous breast carcinoma undergoing assisted fertilization treatment after breast cancer operation and treatment including controlled ovarian stimulation (COS), oocyte retrieval, IVF, and embryo culture and transfer.. Four oocytes were obtained in three COS procedures in the three IVF cycle. All oocytes were fertilized. In the third cycle, two fresh embryos were transferred, and two healthy girls were born at 37 gestational weeks.. Variable dose letrozole-FSH protocol can maintain lower peak estradiol levels and reduce estrogen exposure after breast cancer operation and chemotherapy.

Topics: Adenocarcinoma, Mucinous; Adult; Aromatase Inhibitors; Breast Neoplasms; Embryo Transfer; Estradiol; Female; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Infertility, Female; Letrozole; Menotropins; Nitriles; Ovulation Induction; Pregnancy; Pregnancy, Twin; Triazoles

Women with a breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) mutation are at increased risk for developing breast and ovarian cancer. Various reproductive and hormonal factors have been shown to modify the risk of breast cancer. These studies suggest that estrogen exposure and deprivation are important in the etiology of hereditary cancer. Many patients are interested in the possibility of an adverse effect of fertility treatment on breast cancer risk. It is important to evaluate whether or not infertility per se or exposure to fertility medications increase the risk of breast cancer in genetically predisposed women.. We conducted a matched case-control study of 1,380 pairs of women with a BRCA1 or BRCA2 mutation to determine if a history of infertility, the use of fertility medications, or undergoing in vitro fertilization (IVF) were associated with and increased the risk of breast cancer.. Sixteen percent of the study subjects reported having experienced a fertility problem and 4% had used a fertility medication. Women who had used a fertility medication were not at significantly increased risk of breast cancer (odds ratio [OR] = 1.21; 95% confidence interval [CI] = 0.81-1.82) compared to non-users. Furthermore, there was no risk associated with a history of use of a fertility medication when the subjects were stratified by parity: (OR = 1.29; 95% CI = 0.83-2.01 for nulliparous women and OR = 0.81; 95% CI = 0.30-2.22 for parous women).. The results of this study suggest that the use of fertility medications does not adversely affect the risk of breast cancer among BRCA mutation carriers. Given the small sizes of the exposed subgroups, these findings should be interpreted with caution and confirmatory studies are required.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Bromocriptine; Case-Control Studies; Clomiphene; Estrogens; Female; Fertility Agents, Female; Genes, BRCA1; Genes, BRCA2; Humans; Infertility; Menotropins; Middle Aged; Multivariate Analysis; Mutation; Risk Factors; Young Adult

To determine the association between infertility drug use and invasive breast cancer in a population-based case-control study.. Multicenter case-control study.. Women aged 35 to 64 years in metropolitan Atlanta, Detroit, Los Angeles, Philadelphia, and Seattle.. The 4,575 case patients had histologically confirmed primary invasive breast cancer. The 4,682 control subjects were women without breast cancer identified in the same geographic locations using randomized-digit dialing.. A standardized questionnaire focusing on reproductive health and family history as well as use of oral contraceptives and other hormones and infertility drugs was administered to all subjects. Data on the type of breast cancer were also obtained.. Odds ratios examining the association between use of various infertility drugs and invasive breast cancer.. Overall, a history of infertility drug use was not associated with the risk of developing breast cancer. Compared with women who never used any fertility medication, however, women using human menopausal gonadotropin (hMG) for > or = 6 months or for at least six cycles had a relative risk of breast cancer ranging between 2.7 to 3.8.. Long-term use of certain infertility drugs could adversely affect risk of breast cancer. Additional confirmatory studies are needed.

Topics: Adult; Breast Neoplasms; Case-Control Studies; Female; Fertility Agents, Female; Humans; Interviews as Topic; Logistic Models; Menotropins; Middle Aged; Odds Ratio; Risk Factors

Because of the increased risk of breast cancer for infertile nulliparous women, the suspected promoter role of estradiol in mammary carcinogenesis and the high frequency of ovulation inducer treatments, it was interesting to focus on the risk of breast cancer after such a treatment. We reviewed 32 cases during a retrospective survey in Assisted Reproductive Techniques (ART) centers in France. Because of the small sample size and the few cases published so far, no statistical study could be made. However, many observations may have gone unnoticed or were not published. Two hypotheses can be proposed: (1) the facilitating role of stimulation on potential infra-clinical or un-diagnosed cancers; (2) the initiation of new cancers. Consequently, we propose to establish a register for the follow-up of treated women to monitor the advent of new cancers and to increase the follow-up of patients with other associated risk factors.

Topics: Adult; Breast Neoplasms; Female; Fertilization in Vitro; Humans; Menotropins; Pregnancy; Retrospective Studies

The promoter effect of oestradiol in breast cancer, the higher risk of breast cancer in infertile nulliparous women and the increased use of treatments to include ovulation would suggest that the risk of cancer after this type of treatment might be affected. We thus evaluated the files of patients under 45 years of age treated for breast cancer at the Bergonié Foundation. Six such cases were found. Due to the small number of cases observed to date, no statistical analysis could be performed. Nevertheless, several cases may have gone unrecognized or unpublished. Two hypothesis might be involved: the facilitating effect of stimulation on infraclinical or undiagnosed cancers, initiation of new cancers. We thus propose: a register to follow treated women in order to monitor the appearance of new cases of cancer, improved surveillance in patients with other associated risk factors.

Topics: Adult; Breast Neoplasms; Female; Fertility Agents, Female; Humans; Menotropins; Parity; Population Surveillance; Prognosis; Registries; Retrospective Studies; Risk Factors

Proliferating tumor cells obtained from ovarian, mammary, and endometrial tumors in tissue culture were tested for the influence of proteohormones and steroid hormones on cellular DNA synthesis and cell growth. The gonadotropic hormones stimulated DNA synthesis of ovarian tumor cells by single administration, or in combination with cortisol, up to the 11-fold of the comparable controls. The hormone sensitivity of the cell lines was variable, resulting in individual reaction patterns. There was no correlation to the histological diagnosis of the primary tumors with respect to the grade of differentiation. The results suggest that ovarian tumor cells in tissue culture can maintain sensitivity to organotropic hormones. Compared to the ovarian carcinoma lines, mammary or endometrial tumor cells did not respond to a similar extent. Progesterone decreased DNA synthesis of endometrial carcinoma cells.

Topics: Breast Neoplasms; Cell Division; Chorionic Gonadotropin; Culture Techniques; DNA, Neoplasm; Female; Follicle Stimulating Hormone; Hormones; Humans; Luteinizing Hormone; Menotropins; Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Uterine Neoplasms

The preoperative diagnosis of ectopic ovarian tissue has been reported only once in the literature. In the present case, differential ovarian and adrenal testing was used to diagnose and aberrant ovarian source of persistently elevated plasma estrogen in a patient who had undergone bilateral oophorectomy and adrenalectomy for metastatic breast carcinoma. The ovarian source was diagnosed by stimulation with human chorionic gonadotropin (hCG), and treatment with human menopausal gonadotropin (hMG) prior to surgery was used to facilitate its location at laparotomy.

Topics: Adrenalectomy; Adult; Breast Neoplasms; Carcinoma; Castration; Chorionic Gonadotropin; Estrogens; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menotropins; Ovary